Research Sites Push for Sponsor and CRO Support as Administrative Costs Mount

A new analysis from researchers at the Morehouse School of Medicine, Sanofi, and ICON highlights the growing financial strain on clinical trial sites caused by increasing administrative complexity. As drug studies become more intricate, sites are struggling with the costs of regulatory compliance, vendor oversight, and technology integration, which often outpace traditional budgeting models. Addressing these burdens is critical for the Clinical Research & CRO sector to ensure site sustainability and prevent operational failures that could disrupt drug development pipelines.

The analysis identifies a significant rise in administrative burdens that threaten the financial viability of research sites, particularly those that are research-naïve. Key challenges include the procurement and integration of trial management systems, streamlining access to electronic medical records, and managing an increasing number of specialized vendors. Authors from Morehouse School of Medicine, Sanofi, and ICON noted that as protocols become more demanding, the costs associated with staff resourcing and specialized training for specific trial requirements are becoming increasingly difficult to budget accurately.

Beyond administrative tasks, the report emphasizes that clinical trial site margins are typically narrow, making them highly vulnerable to external economic pressures. General cost inflation and frequent payment delays from sponsors can lead to critical shortages in operating capital, sometimes leaving sites unable to meet payroll or cover basic utility bills. The study suggests that these financial instabilities are exacerbated when sites operate on a project-by-project basis rather than maintaining a consistent pipeline of work.

To mitigate these risks, the authors advocate for a trial funnel approach, where sites maintain a steady volume of new clinical trials to provide financial security and optimize resource allocation. This strategy allows sites to justify long-term investments in infrastructure and technology that improve overall efficiency. By establishing a consistent flow of work, sites can build stronger trust with sponsors and CROs, ensuring they are selected for future studies based on their ability to provide clean data and reliable patient enrollment.

Ultimately, the analysis calls for sponsors and CROs to adopt more long-term strategic thinking to support their site partners. The researchers argue that many financial challenges could be resolved through closer collaboration and more predictable payment schedules. Improving the sustainability of the site ecosystem is presented as a mutual benefit; as sites become more efficient through increased trial volume, they achieve greater profitability, which in turn supports the broader industry's need for high-quality, scalable clinical research capacity.